Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial

Building a tuberculosis-free world: The Lancet Commission on tuberculosis

(2019) Michael J A Reid et al.   LANCET

Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens

(2019) Chawangwa Modongo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R

(2019) Nadine Lübke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review

(2018) Daniel Atwine et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

(2018) Abraham Siika et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy

(2015) Anne-Marie Taburet et al.   CLINICAL INFECTIOUS DISEASES

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

(2014) Jean B. Nachega et al.   CLINICAL INFECTIOUS DISEASES

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

(2014) Beatriz Grinsztejn et al.   LANCET INFECTIOUS DISEASES

Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia

(2013) Julie Bertrand et al.   JOURNAL OF INFECTIOUS DISEASES

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

(2013) Maryline Bonnet et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Integration of Antiretroviral Therapy with Tuberculosis Treatment

(2011) Salim S. Abdool Karim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis

(2011) François-Xavier Blanc et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

(2011) Diane V. Havlir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte dʼIvoire

(2010) Eugène Messou et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

(2010) Patrice Severe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

(2009) L. A. Wenning et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study

(2009) Weerawat Manosuthi et al.   CLINICAL INFECTIOUS DISEASES

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET